Emerging technologies for quality control of cell-based, advanced therapy medicinal products

被引:4
|
作者
Zia, Silvia [1 ]
Pizzuti, Valeria [2 ]
Paris, Francesca [2 ]
Alviano, Francesco [3 ]
Bonsi, Laura [2 ]
Zattoni, Andrea [1 ,4 ,5 ]
Reschiglian, Pierluigi [1 ,4 ,5 ]
Roda, Barbara [1 ,4 ,5 ]
Marassi, Valentina [4 ,5 ]
机构
[1] Stem Sel Srl, Bologna, Italy
[2] Univ Bologna, Dept Med & Surg Sci DIMEC, Bologna, Italy
[3] Univ Bologna, Dept Biomed & Neuromotor Sci DiBiNem, Bologna, Italy
[4] Univ Bologna, Dept Chem G Ciamician, Bologna, Italy
[5] Natl Inst Biostruct & Biosyst INBB, I-00136 Rome, Italy
关键词
Advanced therapy medicinal products (ATMPs); Quality control (QC) of ATMPs; Microfluidic tools for QC of ATMPs; Quality-by-design (QBD); Machine learning and AI; MESENCHYMAL STEM-CELLS; INFRARED-SPECTROSCOPY; STROMAL CELLS; CROSS-FLOW; PROLIFERATION; SEPARATION; SYSTEM; BLOOD; FRACTIONATION; COLLECTION;
D O I
10.1016/j.jpba.2024.116182
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Advanced therapy medicinal products (ATMP) are complex medicines based on gene therapy, somatic cell therapy, and tissue engineering. These products are rapidly arising as novel and promising therapies for a wide range of different clinical applications. The process for the development of well-established ATMPs is challenging. Many issues must be considered from raw material, manufacturing, safety, and pricing to assure the quality of ATMPs and their implementation as innovative therapeutic tools. Among ATMPs, cell-based ATMPs are drugs altogether. As for standard drugs, technologies for quality control, and non-invasive isolation and production of cell-based ATMPs are then needed to ensure their rapidly expanding applications and ameliorate safety and standardization of cell production. In this review, emerging approaches and technologies for quality control of innovative cell-based ATMPs are described. Among new techniques, microfluid-based systems show advantages related to their miniaturization, easy implementation in analytical process and automation which allow for the standardization of the final product.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Formulation of Cell-Based Medicinal Products: A Question of Life or Death?
    Hoogendoorn, Karin H.
    Crommelin, Daan J. A.
    Jiskoot, Wim
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 110 (05) : 1885 - 1894
  • [2] Mesenchymal stem cell-based therapy for autoimmune diseases: emerging roles of extracellular vesicles
    Rad, Fariba
    Ghorbani, Mohammad
    Roushandeh, Amaneh Mohammadi
    Roudkenar, Mehryar Habibi
    MOLECULAR BIOLOGY REPORTS, 2019, 46 (01) : 1533 - 1549
  • [3] Cell-Based Therapy and Genome Editing as Emerging Therapeutic Approaches to Treat Rheumatoid Arthritis
    Chasov, Vitaly
    Ganeeva, Irina
    Zmievskaya, Ekaterina
    Davletshin, Damir
    Gilyazova, Elvina
    Valiullina, Aygul
    Bulatov, Emil
    CELLS, 2024, 13 (15)
  • [5] Methods and practices to diversify cell-based products
    Vertes, Alain A.
    REGENERATIVE MEDICINE, 2017, 12 (08) : 997 - 1013
  • [6] Is the Conjunctiva a Potential Target for Advanced Therapy Medicinal Products?
    Diebold, Yolanda
    Garcia-Posadas, Laura
    PHARMACEUTICS, 2021, 13 (08)
  • [8] Cell based advanced therapeutic medicinal products for bone repair: Keep it simple?
    Leijten, J.
    Chai, Y. C.
    Papantoniou, I.
    Geris, L.
    Schrooten, J.
    Luyten, F. P.
    ADVANCED DRUG DELIVERY REVIEWS, 2015, 84 : 30 - 44
  • [9] The potential of cell-based therapy in lung diseases
    Huleihel, Luai
    Levine, Melanie
    Rojas, Mauricio
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (10) : 1429 - 1440
  • [10] Cell-based therapy in the treatment of musculoskeletal diseases
    Trapana, Justin
    Weinerman, Jonathan
    Lee, Danny
    Sedani, Anil
    Constantinescu, David
    Best, Thomas M.
    Hornicek, Francis J.
    Hare, Joshua M.
    STEM CELLS TRANSLATIONAL MEDICINE, 2024, 13 (10) : 959 - 978